ATE510853T1 - Tlr2-antagonistischer antikörper und dessen verwendung - Google Patents

Tlr2-antagonistischer antikörper und dessen verwendung

Info

Publication number
ATE510853T1
ATE510853T1 AT04765554T AT04765554T ATE510853T1 AT E510853 T1 ATE510853 T1 AT E510853T1 AT 04765554 T AT04765554 T AT 04765554T AT 04765554 T AT04765554 T AT 04765554T AT E510853 T1 ATE510853 T1 AT E510853T1
Authority
AT
Austria
Prior art keywords
directed
antibody
prevention
nucleic acid
treatment
Prior art date
Application number
AT04765554T
Other languages
English (en)
Inventor
Carsten Kirschning
Guangxun Meng
Hermann Wagner
Original Assignee
Univ Muenchen Tech
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen Tech, Amgen Inc filed Critical Univ Muenchen Tech
Application granted granted Critical
Publication of ATE510853T1 publication Critical patent/ATE510853T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04765554T 2003-09-23 2004-09-23 Tlr2-antagonistischer antikörper und dessen verwendung ATE510853T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03021461 2003-09-23
PCT/EP2004/010700 WO2005028509A1 (en) 2003-09-23 2004-09-23 Tlr2 antagonistic antibody and use thereof

Publications (1)

Publication Number Publication Date
ATE510853T1 true ATE510853T1 (de) 2011-06-15

Family

ID=34354423

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04765554T ATE510853T1 (de) 2003-09-23 2004-09-23 Tlr2-antagonistischer antikörper und dessen verwendung

Country Status (4)

Country Link
US (2) US8623353B1 (de)
EP (1) EP1664118B1 (de)
AT (1) ATE510853T1 (de)
WO (1) WO2005028509A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE510853T1 (de) 2003-09-23 2011-06-15 Univ Muenchen Tech Tlr2-antagonistischer antikörper und dessen verwendung
ES2348792T3 (es) 2004-12-10 2010-12-14 Novimmune Sa TERAPIAS COMBINADAS DIRIGIDAS A MÚLTIPLES RECEPTORES TIPO TOLL Y USO DE LAS MISMAS.
EP2139916A1 (de) * 2007-04-26 2010-01-06 Opsona Therapeutics Limited Bindungsepitop des toll-like-rezeptors und zusammensetzungen zum daran binden
PL2173381T3 (pl) 2007-05-14 2014-03-31 Novimmune Sa Polipeptydy o zmodyfikowanych funkcjach efektorowych wiążące się z receptorem Fc
US8580255B2 (en) 2007-06-28 2013-11-12 Opsona Therapeutics Ltd Method for the treatment of rheumatoid arthritis using a TLR2 antagonistic antibody
AU2008285626B2 (en) * 2007-08-03 2013-09-12 Neuramedy Co., Ltd. Use of TLR-2 antagonists for treatment of reperfusion injury and tissue damage
IE20090514A1 (en) * 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
DK2812434T3 (en) * 2012-02-09 2018-07-16 Bavarian Nordic As AGONISTS AND ANTAGONISTS OF TOLL-LIKE RECEPTOR-13 (TLR-13)
GB201205633D0 (en) 2012-03-30 2012-05-16 Opsona Therapeutics Ltd Toll-like receptor 2 binding epitope and binding members thereto
US10047164B2 (en) 2012-10-19 2018-08-14 Opsona Therapeutics Limited Methods and compositions for the treatment of pancreatic cancer
EP2722342A1 (de) 2012-10-19 2014-04-23 Opsona Therapeutics Limited Verfahren und Zusammensetzungen zur Behandlung von Pankreaskrebs
CA2903817A1 (en) 2013-03-12 2014-10-09 Institute of Arthritis Research, LLC Immunologically active polypeptide
BR112016019929A2 (pt) 2014-02-28 2017-10-17 Astellas Pharma Inc ligação de anticorpo biespecífico ao tlr2 humano e tlr4 humano
US20170137820A1 (en) * 2014-08-06 2017-05-18 Bavarian Nordic A/S Agonists and antagonists of toll-like receptor (tlr) 13
EA201990253A1 (ru) * 2015-07-13 2019-06-28 Юниверсите Лаваль Гуманизированные антитела против s100a9 и их применение
US10196453B2 (en) * 2016-05-20 2019-02-05 University Of Virginia Patent Foundation Compositions and methods for treating Clostridium difficile infection
WO2018099614A1 (en) 2016-12-02 2018-06-07 Opsona Therapeutics Limited Methods and compositions for the treatment of myelodysplastic syndrome
EP3583949A1 (de) 2018-06-19 2019-12-25 Opsona Therapeutics Limited Toll-like rezeptor 2 (tlr2) antagonisten zur behandlung von ovarialkrebs
WO2020075171A1 (en) 2018-10-11 2020-04-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Bacteria expressing single chain antibodies against toll-like receptors
CN111440240A (zh) * 2020-03-30 2020-07-24 中国人民解放军南部战区总医院 一种单克隆抗体及其制备方法和应用
CN111393530A (zh) * 2020-03-30 2020-07-10 中国人民解放军南部战区总医院 新人源tlr2胞外区段单克隆抗体及其制备方法和应用
US20220257633A1 (en) * 2021-02-17 2022-08-18 The Provost, Fellows, Foundation Scholars, & The O Method of treating age-related macular degeneration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9927332D0 (en) 1999-11-18 2000-01-12 Leiv Eiriksson Nyfotek As Novel antibody and uses thereof
JP4790937B2 (ja) 2001-07-09 2011-10-12 ティーピーオー ホンコン ホールディング リミテッド 反射電極を形成する方法及び液晶表示装置
AU2003209623A1 (en) * 2002-02-19 2003-09-09 Yeda Research And Development Co. Ltd. Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation
ATE510853T1 (de) 2003-09-23 2011-06-15 Univ Muenchen Tech Tlr2-antagonistischer antikörper und dessen verwendung
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
ES2348792T3 (es) * 2004-12-10 2010-12-14 Novimmune Sa TERAPIAS COMBINADAS DIRIGIDAS A MÚLTIPLES RECEPTORES TIPO TOLL Y USO DE LAS MISMAS.

Also Published As

Publication number Publication date
US9458234B2 (en) 2016-10-04
EP1664118B1 (de) 2011-05-25
US20140343256A1 (en) 2014-11-20
US8623353B1 (en) 2014-01-07
EP1664118A1 (de) 2006-06-07
WO2005028509A1 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
ATE510853T1 (de) Tlr2-antagonistischer antikörper und dessen verwendung
EA201000424A1 (ru) Антитела к il-23
MX2007001338A (es) Anticuerpos antagonistas de il-17.
NZ594682A (en) Fully human antibodies specific to cadm1
AR075790A2 (es) Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural)
CY1117036T1 (el) Ανθρωπινα αντισωματα που προσδενουν cxcr4 και χρησεις αυτων
IL200373A (en) A monoclonal antibody that binds to 3erbb and a pharmacological preparation that includes the same to inhibit 3erbb signaling in humans
NZ603499A (en) Human cytomegalovirus neutralizing antibodies and uses thereof
CO6180445A2 (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
TW200503721A (en) Aminoquinoline compounds
NZ596295A (en) Anti-5T4 antibodies and uses thereof
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
PH12013500347A1 (en) Antibodies to matrix metalloproteinase 9
GEP20104922B (en) Antibodies to m-csf
ATE382053T1 (de) System zur antikörperexpression und- synthese
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
NZ601271A (en) Cd127 binding proteins
NZ595792A (en) Antibodies specific to cadherin-17
MX2009001110A (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos.
BRPI0409879A (pt) composições e métodos para imunoterapia especìfica wt1
MD20140108A2 (ro) Anticorpi împotriva metaloproteinazei 9 matriciale
GB201005064D0 (en) Biological products
EA201491724A1 (ru) Антитела, нейтрализующие rsv, mpv и pvm, и их применения
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
TW200801038A (en) Immunoglobulins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties